Advancing obesity drug discovery: Cell-based assays for GLP-1 and the G-Suite
9 January 2025 | By Eurofins DiscoverX
Discover innovative and validated solutions for developing obesity therapeutics. These solutions enable effective screening, characterisation, and potency testing for commercial lot release of novel drugs targeting GPCRs, including GLP-1, GIP, and glucagon receptors.